(VIANEWS) – T. Rowe Price Group (TROW), ANI Pharmaceuticals (ANIP), Terreno Realty Corporation (TRNO) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. T. Rowe Price Group (TROW)
15% sales growth and 18.72% return on equity
T. Rowe Price Group, Inc. is a publicly owned investment manager. The firm provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. It launches and manages equity and fixed income mutual funds. The firm invests in the public equity and fixed income markets across the globe. It employs fundamental and quantitative analysis with a bottom-up approach. The firm utilizes in-house and external research to make its investments. It employs socially responsible investing with a focus on environmental, social, and governance issues. It makes investment in late-stage venture capital transactions and usually invests between $3 million and $5 million. The firm was previously known as T. Rowe Group, Inc. and T. Rowe Price Associates, Inc. T. Rowe Price Group, Inc. was founded in 1937 and is based in Baltimore, Maryland, with additional offices in Colorado Springs, Colorado; Owings Mills, Maryland; San Francisco, California; New York, New York; Philadelphia, Pennsylvania; Tampa, Florida; Toronto, Ontario; Hellerup, Denmark; Amsterdam, The Netherlands; Luxembourg, Grand Duchy of Luxembourg; Zurich, Switzerland; Dubai, United Arab Emirates; London, United Kingdom; Sydney, New South Wales; Hong Kong; Tokyo, Japan; Singapore; Frankfurt, Shanghai, China; Germany, Madrid, Spain, Milan, Italy, Stockholm, Sweden, Melbourne, Australia, Amsterdam, Netherlands and Washington, DC.
Earnings Per Share
As for profitability, T. Rowe Price Group has a trailing twelve months EPS of $7.76.
PE Ratio
T. Rowe Price Group has a trailing twelve months price to earnings ratio of 14.84. Meaning, the purchaser of the share is investing $14.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.72%.
2. ANI Pharmaceuticals (ANIP)
14% sales growth and 5.9% return on equity
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Earnings Per Share
As for profitability, ANI Pharmaceuticals has a trailing twelve months EPS of $1.19.
PE Ratio
ANI Pharmaceuticals has a trailing twelve months price to earnings ratio of 47.23. Meaning, the purchaser of the share is investing $47.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.9%.
Volume
Today’s last reported volume for ANI Pharmaceuticals is 280044 which is 12.97% below its average volume of 321814.
Sales Growth
ANI Pharmaceuticals’s sales growth is 6.4% for the ongoing quarter and 14% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.4%, now sitting on 538.95M for the twelve trailing months.
3. Terreno Realty Corporation (TRNO)
14% sales growth and 5.24% return on equity
Terreno Realty Corporation (“Terreno”, and together with its subsidiaries, the “Company”) acquires, owns and operates industrial real estate in six major coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. All square feet, acres, occupancy and number of properties disclosed in these notes to the consolidated financial statements are unaudited. As of December 31, 2023, the Company owned 259 buildings aggregating approximately 16.0 million square feet, 45 improved land parcels consisting of approximately 152.4 acres, seven properties under development or redevelopment and approximately 62.7 acres of land entitled for future development. The Company is an internally managed Maryland corporation and elected to be taxed as a real estate investment trust (“REIT”) under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”), commencing with its taxable year ended December 31, 2010.
Earnings Per Share
As for profitability, Terreno Realty Corporation has a trailing twelve months EPS of $1.8.
PE Ratio
Terreno Realty Corporation has a trailing twelve months price to earnings ratio of 38.63. Meaning, the purchaser of the share is investing $38.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.24%.
Sales Growth
Terreno Realty Corporation’s sales growth is 15.6% for the ongoing quarter and 14% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.5%, now sitting on 348.68M for the twelve trailing months.
Volume
Today’s last reported volume for Terreno Realty Corporation is 513616 which is 22.64% below its average volume of 663995.
Yearly Top and Bottom Value
Terreno Realty Corporation’s stock is valued at $69.53 at 16:22 EST, below its 52-week high of $71.63 and way higher than its 52-week low of $50.42.
4. Artisan Partners Asset Management (APAM)
12.6% sales growth and 55.84% return on equity
Artisan Partners Asset Management Inc. is publicly owned investment manager. It provides its services to pension and profit sharing plans, trusts, endowments, foundations, charitable organizations, government entities, private funds and non-U.S. funds, as well as mutual funds, non-U.S. funds and collective trusts. It manages separate client-focused equity and fixed income portfolios. The firm invests in the public equity and fixed income markets across the globe. It invests in growth and value stocks of companies across all market capitalization. For fixed income component of its portfolio the firm invests in non-investment grade corporate bonds and secured and unsecured loans. It employs fundamental analysis to create its portfolios. Artisan Partners Asset Management Inc. was founded in 1994 and is based in Milwaukee, Wisconsin with additional offices in Atlanta, Georgia; New York City; San Francisco, California; Leawood, Kansas; and London, United Kingdom.
Earnings Per Share
As for profitability, Artisan Partners Asset Management has a trailing twelve months EPS of $3.35.
PE Ratio
Artisan Partners Asset Management has a trailing twelve months price to earnings ratio of 11.89. Meaning, the purchaser of the share is investing $11.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 55.84%.
Sales Growth
Artisan Partners Asset Management’s sales growth is 11.2% for the current quarter and 12.6% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 16% and 16.7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.5%, now sitting on 1.03B for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Aug 16, 2024, the estimated forward annual dividend rate is 2.84 and the estimated forward annual dividend yield is 7.13%.
5. Stifel Financial Corporation (SF)
11.4% sales growth and 10.42% return on equity
Stifel Financial Corp., a financial services and bank holding company, provides retail and institutional wealth management, and investment banking services to individual investors, corporations, municipalities, and institutions in the United States and internationally. It operates in three segments: Global Wealth Management, Institutional Group, and Other. The company provides private client services, including securities transaction and financial planning services; institutional equity and fixed income sales, trading and research, and municipal finance services; investment banking services, such as mergers and acquisitions, public offerings, and private placements; and retail and commercial banking services comprising personal and commercial lending programs, as well as deposit accounts. It participates in and manages underwritings for corporate and public finance; and offers financial advisory and securities brokerage services. The company was founded in 1890 and is headquartered in Saint Louis, Missouri.
Earnings Per Share
As for profitability, Stifel Financial Corporation has a trailing twelve months EPS of $4.72.
PE Ratio
Stifel Financial Corporation has a trailing twelve months price to earnings ratio of 18.18. Meaning, the purchaser of the share is investing $18.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.42%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.5%, now sitting on 4.55B for the twelve trailing months.
Yearly Top and Bottom Value
Stifel Financial Corporation’s stock is valued at $85.79 at 16:22 EST, below its 52-week high of $90.00 and way higher than its 52-week low of $54.81.
6. U.S. Physical Therapy (USPH)
9.2% sales growth and 5.17% return on equity
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. The company was founded in 1990 and is based in Houston, Texas.
Earnings Per Share
As for profitability, U.S. Physical Therapy has a trailing twelve months EPS of $0.99.
PE Ratio
U.S. Physical Therapy has a trailing twelve months price to earnings ratio of 85.44. Meaning, the purchaser of the share is investing $85.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.17%.
7. CONMED Corporation (CNMD)
5.6% sales growth and 11.86% return on equity
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Earnings Per Share
As for profitability, CONMED Corporation has a trailing twelve months EPS of $3.14.
PE Ratio
CONMED Corporation has a trailing twelve months price to earnings ratio of 23.82. Meaning, the purchaser of the share is investing $23.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.86%.
Yearly Top and Bottom Value
CONMED Corporation’s stock is valued at $74.79 at 16:22 EST, way below its 52-week high of $117.27 and way higher than its 52-week low of $61.05.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Sep 16, 2024, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 1.07%.
